Play all audios:
ABSTRACT TGF_α_/p53+/− transgenic mice represent a genetically engineered mouse model for pancreatic adenocarcinoma. The tumors develop a characteristic pattern of secondary genetic changes.
From one of these tumors, the permanent cell line TD2 was established. Here, we describe in detail the genetic changes by molecular–cytogenetic techniques. The original tumor-specific CGH
profile has been retained unchanged. The most characteristic aberration pattern bears chromosome 11. _Egfr_, localized on proximal chromosome 11, is amplified two to three times and leads to
an easily identifiable, stable marker chromosome with a large amplification unit, which is present in each metaphase. The wild-type _p53_ gene on distal chromosome 11 is lost. The
_p16__Ink4a_ locus on chromosome 4 is hypermethylated. For _c-Myc_ a 15-fold amplification, present in a 1.65 Mb amplification unit, is detected on chromosome 15. Transition between presence
in the form of several double minutes, DMs, or a single homogeneously staining region, HSR, was observed for _c-Myc_. Molecular–cytogenetic analysis of both amplification units show that
_Egfr_ amplification and _c-Myc_ amplification represent two alternative modes by which genes get amplified in tumor cells. The expression level of the respective genes was proven by
Northern blot analysis. The cell line TD2 represents a valuable _in vitro_ model for pancreatic adenocarcinoma. Access through your institution Buy or subscribe This is a preview of
subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 50 print issues and online access $259.00 per year only
$5.18 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout
ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS GΑ15 IN EARLY ONSET OF
PANCREATIC DUCTAL ADENOCARCINOMA Article Open access 21 July 2021 HUMAN CHROMOSOME 3P21.3 CARRIES _TERT_ TRANSCRIPTIONAL REGULATORS IN PANCREATIC CANCER Article Open access 28 July 2021
COMBINED DELETION OF MEN1, ATRX AND PTEN TRIGGERS DEVELOPMENT OF HIGH-GRADE PANCREATIC NEUROENDOCRINE TUMORS IN MICE Article Open access 12 April 2024 REFERENCES * Bardeesy N, Morgan J,
Sinha M, Signoretti S, Srivastava S, Loda M, Merlino G and DePinho RA . (2002). _Mol.Cell. Biol._, 22, 635–643. * Bardeesy N, Sharpless NE, DePinho RA and Merlino G . (2001). _Semin. Cancer
Biol._, 11, 201–218. * Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE . (1994). _Nat. Genet._, 8, 27–32. * Curtis LJ, Yong L,
Gerbault-Sereau M, Kuick R, Dutrillaux A-M, Goubin G, Fawcett J, Cram S, Dutrillaux B, Hanash S and Muleris M . (1998). _Genomics_, 53, 42–55. * Gilmore TD . (1999). _Oncogene_, 18,
6842–6844. * Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G and Schmid RM . (2002). _Gastroenterology_, 123, 2052–2063. * Hajkova P, EI Maarri O, Engemann S, Oswald J, Olek A
and Walter J . (2002). _Methods Mol. Biol._, 200, 143–154. * Hellman A, Zlotorynski E, Scherer SW, Cheung J, Vincent JB, Smith DI, Trakhtenbrot L and Kerem B . (2002). _Cancer Cell_, 1,
89–97. * Hruban RH, Goggins M, Parsons J and Kern SE . (2000). _Clin. Cancer Res._, 6, 2969–2972. * Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D .
(1992). _Science_, 258, 818–821. * Ma C, Martin S, Trask B and Hamlin JL . (1993). _Genes Dev._, 7, 605–620. * Maurer BJ, Lai E, Hamkalo BA, Hood L and Attardi G . (1987). _Nature_, 327,
434–437. * Patel AC, Anna CH, Foley JF, Stockton PS, Tyson FL, Barrett JC and Devereux TR . (2000). _Carcinogenesis_, 21, 1691–1700. * Paulson TG, Almasan A, Brody LL and Wahl GM . (1998).
_Mol. Cell. Biol._, 18, 3089–3100. * Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL and Lee DC . (1990). _Cell_, 61, 1121–1135. * Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD and
Brinster RL . (1991). _Proc. Natl. Acad. Sci. USA_, 88, 93–97. * Schwab M . (1999). _Semin. Cancer Biol._, 9, 319–325. * Steinle AU, Weidenbach H, Wagner M, Adler G and Schmid RM . (1999).
_Gastroenterology_, 116, 420–430. * Toledo F, Le Roscouet D, Buttin G and Debatisse M . (1992). _EMBO J._, 11, 2665–2673. * Wagner M, Greten FR, Weber CK, Koschnick S, Mattfeldt T, Deppert
W, Kern H, Adler G and Schmid RM . (2001). _Genes Dev._, 15, 286–293. * Wahl GM . (1989). _Cancer Res._, 49, 1333–1340. * Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiao PJ .
(1999). _Clin. Cancer Res._, 5, 119–127. * Weaver ZA, McCormack SJ, Liyanage M, du MS, Coleman A, Schrock E, Dickson RB and Ried T . (1999). _Genes Chromosom. Cancer_, 25, 251–260. * Wu Y,
Renard CA, Apiou F, Huerre M, Tiollais P, Dutrillaux B and Buendia MA . (2002). _Oncogene_, 21, 1518–1526. Download references ACKNOWLEDGEMENTS We thank Antje Kollak, Alexandra Kilian and
Beate Knobl for excellent technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft SFB 518 (Teilprojekt B6) and IZKF Ulm (Teilprojekt C4) to RMS.
AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Human Genetics, University of Ulm, Ulm, D-89069, Germany Bettina Schreiner & Horst Hameister * Department of Pharmacology,
University of California, San Diego, La Jolla, 92093-0636, CA, USA Florian R Greten * Department of Internal Medicine II, Technical University of Munich, Munich, D-81675, Germany Florian R
Greten & Roland M Schmid * Department of Internal Medicine I, University of Ulm, Ulm, D-89069, Germany Dorotthe M Baur, Alexander A Fingerle, Ulrich Zechner & Roland M Schmid *
Institute of Human Genetics, University of Würzburg, Würzburg, D-97074, Germany Christian Böhm & Michael Schmid Authors * Bettina Schreiner View author publications You can also search
for this author inPubMed Google Scholar * Florian R Greten View author publications You can also search for this author inPubMed Google Scholar * Dorotthe M Baur View author publications You
can also search for this author inPubMed Google Scholar * Alexander A Fingerle View author publications You can also search for this author inPubMed Google Scholar * Ulrich Zechner View
author publications You can also search for this author inPubMed Google Scholar * Christian Böhm View author publications You can also search for this author inPubMed Google Scholar *
Michael Schmid View author publications You can also search for this author inPubMed Google Scholar * Horst Hameister View author publications You can also search for this author inPubMed
Google Scholar * Roland M Schmid View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Roland M Schmid. RIGHTS AND
PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Schreiner, B., Greten, F., Baur, D. _et al._ Murine pancreatic tumor cell line TD2 bears the characteristic pattern
of genetic changes with two independently amplified gene loci. _Oncogene_ 22, 6802–6809 (2003). https://doi.org/10.1038/sj.onc.1206836 Download citation * Received: 11 April 2003 * Revised:
02 June 2003 * Accepted: 02 June 2003 * Published: 02 October 2003 * Issue Date: 02 October 2003 * DOI: https://doi.org/10.1038/sj.onc.1206836 SHARE THIS ARTICLE Anyone you share the
following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer
Nature SharedIt content-sharing initiative KEYWORDS * murine pancreatic tumor cell line * _c-Myc_ and _Egfr_ amplification * _p53_ deletion * _p16__Ink4a_ hypermethylation